Format

Send to

Choose Destination
Semin Cancer Biol. 2019 Nov 4. pii: S1044-579X(19)30148-8. doi: 10.1016/j.semcancer.2019.10.019. [Epub ahead of print]

Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.

Author information

1
Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India. Electronic address: kramanathan@vit.ac.in.
2
Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.
3
Department of Computer Science, Purdue University, West Lafayette, IN, 47907, United States; Department of Chemistry Education, Sunchon National University, Suncheon 57922, Republic of Korea.
4
Department of Biological Science, Purdue University, West Lafayette, IN, 47907, United States; Department of Computer Science, Purdue University, West Lafayette, IN, 47907, United States; Purdue University, Center for Cancer Research, West Lafayette, IN, 47907, United States; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 45229, United States.

Abstract

A pre-eminent subtype of lung carcinoma, Non-small cell lung cancer accounts for paramount causes of cancer-associated mortality worldwide. Undeterred by the endeavour in the treatment strategies, the overall cure and survival rates for NSCLC remain substandard, particularly in metastatic diseases. Moreover, the emergence of resistance to classic anticancer drugs further deteriorates the situation. These demanding circumstances culminate the need of extended and revamped research for the establishment of upcoming generation cancer therapeutics. Drug repositioning introduces an affordable and efficient strategy to discover novel drug action, especially when integrated with recent systems biology driven stratagem. This review illustrates the trendsetting approaches in repurposing along with their numerous success stories with an emphasize on the NSCLC therapeutics. Indeed, these novel hits, in combination with conventional anticancer agents, will ideally make their way the clinics and strengthen the therapeutic arsenal to combat drug resistance in the near future.

KEYWORDS:

Drug Discovery; Drug repurposing; Drug resistance; Lung cancer; Repositioned hits

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center